Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares are up during Tuesday’s premarket session following positive interim results from one of its Phase 3 trials.

The stock’s rise comes as the company is reportedly making significant strides in its clinical development.

Vertex’s Phase 3 RAINIER Trial Success

Vertex announced that its ongoing Phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy met its primary objective, achieving a 52% reduction from baseline in urine protein to creatinine ratio (UPCR) at Week 36.

Additionally, the trial demonstrated a statistically significant 49.8% UPCR reduction compared to placebo, with 85.1% of patients with baseline hematuria achieving resolution.

The positive data from the trial also showed that patients treated with povetacicept experienced a 77.4% reduction from baseline in serum galactose-deficient IgA1.

The FDA has granted a rolling review of the Biologics License Application for povetacicept, with Vertex planning to complete its full submission by the end of March.

Analyst Sees Clear Win For Vertex

William Blair wrote ...